The effects of TIMP-1 and -2 on canine chondrocytes cultured in three-dimensional agarose culture system

Osteoarthritis and Cartilage

Volumn 11, Issue 9, 2003, Pages 625-635

  Kuroki, K ^a   Cook, J L ^a   Kreeger, J M ^a   Tomlinson, J L ^a  

^a UNIVERSITY OF MISSOURI   (United States)

Author keywords

Chondrocytes; Interleukin 1 ; Osteoarthritis; Tissue inhibitor of metalloproteinases

Indexed keywords

AGAROSE; GLYCOSAMINOGLYCAN; INTERLEUKIN 1BETA; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANIMAL CELL; ANIMAL TISSUE; BIOCHEMISTRY; CARTILAGE CELL; CELL CULTURE; CELL STRUCTURE; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CULTURE MEDIUM; DOG; ENZYME SYNTHESIS; EXTRACELLULAR MATRIX; IMMUNOHISTOCHEMISTRY; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; REVIEW; STATISTICAL SIGNIFICANCE; TIME;

EID: 0041885332     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1063-4584(03)00116-X     Document Type: Article

References (58)

1. Cawston TE. Metalloproteinase inhibitors and the prevention of connective tissue breakdown. Pharmacol Ther 1996;70:163-82.
2. Knauper V, Lopez-Otin C, Smith B, Knight G, Murphy G. Biochemical characterization of human collagenase-3. J Biol Chem 1996;271:1544-50.
3. Murphy G, Hembry RM, Hughes CE, Fosang AJ, Hardingham TE. Role and regulation of metalloproteinases in connective tissue turnover. Biochem Soc Trans 1990;18:812-5.
4. Woessner JF Jr, Gunja-Smith Z. Role of metalloproteinases in human osteoarthritis. J Rheumatol 1991; 27(Suppl):99-101.
5. Dean DD, Martel-Pelletier J, Pelletier JP, Howell DS, Woessner JF Jr. Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. J Clin Invest 1989;84:678-85.
6. Pelletier JP, Mineau F, Faure MP, Martel-Pelletier J. Imbalance between the mechanisms of activation and inhibition of metalloproteases in the early lesions of experimental osteoarthritis. Arthritis Rheum 1990; 33:1466-76.
7. Vincenti MP, Clark IM, Brinckerhoff CE. Using inhibitors of metalloproteinases to treat arthritis. Easier said than done? Arthritis Rheum 1994;37:1115-26.
8. Cawston TE, Rowan A. Prevention of cartilage breakdown by matrix metalloproteinase inhibition-a realistic therapeutic target? Br J Rheumatol 1998; 37:353-6.
9. Hughes CE, Little CB, Buttner FH, Bartnik E, Caterson B. Differential expression of aggrecanase and matrix metalloproteinase activity in chondrocytes isolated from bovine and porcine articular cartilage. J Biol Chem 1998;273:30576-82.
10. Duncan SJ, Reynolds JJ. The effects of razoxane (ICRF 159) on the production of collagenase and inhibitor (TIMP) by stimulated rabbit articular chondrocytes. Biochem Pharmacol 1983;32:3853-8.
11. Yamada H, Watanabe K, Saito T, Hayashi H, Niitani Y, Kikuchi T, et al. Esculetin (dihydroxycoumarin) inhibits the production of matrix metalloproteinases in cartilage explants, and oral administration of its pro-drug, CPA-926, suppresses cartilage destruction in rabbit experimental osteoarthritis. J Rheumatol 1999; 26:654-62.
12. Bonassar LJ, Sandy JD, Lark MW, Plaas AH, Frank EH, Grodzinsky AJ. Inhibition of cartilage degradation and changes in physical properties induced by IL-1β and retinoic acid using matrix metalloproteinase inhibitors. Arch Biochem Biophys 1997; 344:404-12.
13. Bottomley KM, Borkakoti N, Bradshaw D, Brown PA, Broadhurst MJ, Budd JM, et al. Inhibition of bovine nasal cartilage degradation by selective matrix metalloproteinase inhibitors. Biochem J 1997; 323:483-8.
14. Caputo CB, Sygowski LA, Wolanin DJ, Patton SP, Caccese RG, Shaw A, et al. Effect of synthetic metalloprotease inhibitors on cartilage autolysis in vitro. J Pharmacol Exp Ther 1987;240:460-5.
15. Ellis AJ, Curry VA, Powell EK, Cawston TE. The prevention of collagen breakdown in bovine nasal cartilage by TIMP, TIMP-2 and a low molecular weight synthetic inhibitor. Biochem Biophys Res Commun 1994;201:94-101.
16. Greenwald RA, Moak SA, Ramamurthy NS, Golub LM. Tetracyclines suppress matrix metalloproteinase activity in adjuvant arthritis and in combination with flurbiprofen, ameliorate bone damage. J Rheumatol 1992;19:927-38.
17. Cook JL, Kreeger JM, Payne JT, Tomlinson JL. Three-dimensional culture of canine articular chondrocytes on multiple transplantable substrates. Am J Vet Res 1997;58:419-24.
18. Anderson CC, Cook JL, Kreeger JM, Tomlinson JL, Wagner-Mann CC. In vitro effects of glucosamine and acetylsalicylate on canine chondrocytes in three-dimensional culture. Am J Vet Res 1999;60:1546-51.
19. Cook JL, Anderson CC, Kreeger JM, Tomlinson JL. Effects of human recombinant interleukin-1β on canine articular chondrocytes in three-dimensional culture. Am J Vet Res 2000;61:766-70.
20. Tomlinson JL, Cook JL, Kuroki K, Kreeger JM, Anderson MA. Biochemical characterization of cartilage affected by osteochondritis dissecans in the humeral head of dogs. Am J Vet Res 2001; 62:876-81.
21. Kuroki K, Kreeger JM, Cook JL, Tomlinson JL, Johnson GC, Pace LW, et al. Immunohistochemical analysis of matrix metalloproteinase-1, -3, and -13 in naturally occurring cartilaginous tumors of dogs. Am J Vet Res 2002;63:1285-91.
22. Fernandes JC, Martel-Pelletier J, Lascau-Coman V, Moldovan F, Jovanovic D, Raynauld JP, et al. Collagenase-1 and collagenase-3 synthesis in normal and early experimental osteoarthritic canine cartilage: an immunohistochemical study. J Rheumatol 1998;25:1585-94.
23. Farndale RW, Buttle DJ, Barrett AJ. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim Biophys Acta 1986;883:173-7.
24. Natarajan N, Shambaugh GE 3rd, Elseth KM, Haines GK, Radosevich JA. Adaptation of the diphenylamine (DPA) assay to a 96-well plate tissue culture format and comparison with the MTT assay. Biotechniques 1994;17:167-71.
25. Reddy GK, Enwemeka CS. A simplified method for the analysis of hydroxyproline in biological tissues. Clin Biochem 1996;29:225-9.
26. Benya PD, Shaffer JD. Dedifferentiated chondrocytes reexpress the differentiated collagen phenotype when cultured in agarose gels. Cell 1982;30:215-24.
27. Wang L, Verbruggen G, Almqvist KF, Elewaut D, Broddelez C, Veys EM. Flow cytometric analysis of the human articular chondrocyte phenotype in vitro. Osteoarthritis Cartilage 2001;9:73-84.
28. Billinghurst RC, Dahlberg L, Ionescu M, Reiner A, Bourne R, Rorabeck C, et al. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest 1997;99:1534-45.
29. Flannery CR, Lark MW, Sandy JD. Identification of a stromelysin cleavage site within the interglobular domain of human aggrecan. Evidence for proteolysis at this site in vivo in human articular cartilage. J Biol Chem 1992;267:1008-14.
30. Williamson RA, Marston FA, Angal S, Koklitis P, Panico M, Morris HR, et al. Disulphide bond assignment in human tissue inhibitor of metalloproteinases (TIMP). Biochem J 1990;268:267-74.
31. Murphy G, Houbrechts A, Cockett MI, Williamson RA, O'Shea M, Docherty AJ. The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinases inhibitory activity. Biochemistry 1991; 30:8097-102.
32. Aulthouse AL, Beck M, Griffey E, Sanford J, Arden K, Machado MA, et al. Expression of the human chondrocyte phenotype in vitro. In Vitro Cell Dev Biol 1989;25:659-68.
33. Buschmann MD, Gluzband YA, Grodzinsky AJ, Kimura JH, Hunziker EB. Chondrocytes in agarose culture synthesize a mechanically functional extracellular matrix. J Orthop Res 1992;10:745-58.
34. Pujol JP, Loyau G. Interleukin-1 and osteoarthritis. Life Sci 1987;41:1187-98.
35. Hubbard JR, Steinberg JJ, Bednar MS, Sledge CB. Effect of purified human interleukin-1 on cartilage degradation. J Orthop Res 1988;6:180-7.
36. Verschure PJ, Van Noorden CJ. The effects of interleukin-1 on articular cartilage destruction as observed in arthritic disease, and its therapeutic control. Clin Exp Rheumatol 1990;8:303-13.
37. Beekman B, Verzijl N, de Roos JA, TeKoppele JM. Matrix degradation by chondrocytes cultured in alginate: IL-1 beta induces proteoglycan degradation and proMMP synthesis but does not result in collagen degradation. Osteoarthritis Cartilage 1998;6:330-40.
38. Goldring MB. Degradation of articular cartilage in culture: regulatory factors. In: Woessner JF, Howell DS, Eds. Joint Cartilage Degradation: Basic and Clinical Aspects. New York: Marcel Dekker 1993;281-345.
39. Gunther M, Haubeck HD, van de Leur E, Blaser J, Bender S, Gutgemann I, et al. Transforming growth factor beta 1 regulates tissue inhibitor of metalloproteinases-1 expression in differentiated human articular chondrocytes. Arthritis Rheum 1994; 37:395-405.
40. Wang L, Almqvist KF, Veys EM, Verbruggen G. Control of extracellular matrix homeostasis of normal cartilage by a TGFbeta autocrine pathway. Validation of flow cytometry as a tool to study chondrocyte metabolism in vitro. Osteoarthritis Cartilage 2002; 10:188-98.
41. Massova I, Kotra LP, Fridman R, Mobashery S. Matrix metalloproteinases: structures, evolution, and diversification. FASEB J 1998;12:1075-95.
42. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000;1477:267-83.
43. Taskiran D, Stefanovic-Racic M, Georgescu H, Evans C. Nitric oxide mediates suppression of cartilage proteoglycan synthesis by interleukin-1. Biochem Biophys Res Commun 1994;200:142-8.
44. Blavier L, Henriet P, Imren S, Declerck YA. Tissue inhibitors of matrix metalloproteinases in cancer. Ann NY Acad Sci 1999;878:108-19.
45. Bahrami S, Stratmann U, Wiesmann HP, Mokrys K, Bruckner P, Szuwart T. Periosteally derived osteoblast-like cells differentiate into chondrocytes in suspension culture in agarose. Anat Rec 2000; 259:124-30.
46. Kuhn K, Hashimoto S, Lotz M. IL-1 beta protects human chondrocytes from CD95-induced apoptosis. J Immunol 2000;164:2233-9.
47. Blanco FJ, Lotz M. IL-1-induced nitric oxide inhibits chondrocyte proliferation via PGE2. Exp Cell Res 1995;218:319-25.
48. Arner EC, Pratta MA, Trzaskos JM, Decicco CP, Tortorella MD. Generation and characterization of aggrecanase. A soluble, cartilage-derived aggrecandegrading activity. J Biol Chem 1999;274:6594-601.
49. Kozaci LD, Buttle DJ, Hollander AP. Degradation of type II collagen, but not proteoglycan, correlates with matrix metalloproteinase activity in cartilage explant cultures. Arthritis Rheum 1997;40:164-74.
50. Abbaszade I, Liu RQ, Yang F, Rosenfeld SA, Ross OH, Link JR, et al. Cloning and characterization of ADAMTS11, an aggrecanase from the ADAMTS family. J Biol Chem 1999;274:23443-50.
51. Tortorella MD, Burn TC, Pratta MA, Abbaszade I, Hollis JM, Liu R, et al. Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. Science 1999;284:1664-6.
52. Tortorella MD, Malfait AM, Deccico C, Amer E. The role of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage degradation. Osteoarthritis Cartilage 2001;9:539-52.
53. Tortorella MD, Pratta M, Liu RQ, Austin J, Ross OH, Abbaszade I, et al. Sites of aggrecan cleavage by recombinant human aggrecanase-1 (ADAMTS-4). J Biol Chem 2000;275:18566-73.
54. Malfait AM, Liu RQ, Ijiri K, Komiya S, Tortorella MD. Inhibition of ADAM-TS4 and ADAM-TS5 prevents aggrecan degradation in osteoarthritic cartilage. J Biol Chem 2002;277:22,201-8.
55. Kashiwagi M, Tortorella M, Nagase H, Brew K. TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). J Biol Chem 2001; 276:12501-4.
56. Hashimoto G, Aoki T, Nakamura H, Tanzawa K, Okada Y. Inhibition of ADAMTS4 (aggrecanase-1) by tissue inhibitors of metalloproteinases (TIMP-1, 2, 3 and 4). FEBS Lett 2001;494:192-5.
57. Schett G, Hayer S, Tohidast-Akrad M, Schmid BJ, Lang S, Turk B, et al. Adenovirus-based over-expression of tissue inhibitor of metalloproteinase 1 reduces tissue damage in the joints of tumor necrosis factor α transgenic mice. Arthritis Rheum 2001; 44:2888-98.
58. Apparailly F, Noel D, Millet V, Baker AH, Lisignoli G, Jacquet C, et al. Paradoxical effects of tissue inhibitor of metalloproteinases 1 gene transfer in collagen-induced arthritis. Arthritis Rheum 2001;44:1444-54.